Aripiprazole (Abilify) PDF

Preview

Summary

Download Aripiprazole (Abilify) PDF

Description

CLIENT MEDICATION FORM Trade & Generic Names

Aripiprazole (Abilify)

Pharmacokinetics (absorption, [onset, peak, duration], distribution, metabolism, excretion) Route: PO; Onset: Unknown; Peak: 3-5 hours; Duration: Unknown; Half-life: About 75 hours in patients with normal metabolism.

Classification

Therapeutic class: Antipsychotics Pharmacologic class: Quinolinone derivatives Client Order (include dosage, route, & frequency) 5 mg PO HS

Recommended Dosage Range

Initially, 2 mg PO daily; increase to 5 mg PO daily after 2 days, then to recommended dose of 10 mg after 2 additional days. May titrate to maximum daily dose of 30 mg in 5-mg increments every 5 days IV medication administration flow rate & dilution N/A Uses/Indications (individualize for client)

To treat psychosis

Side Effects Seizures, bradycardia, neutropenia, suicidal ideation and behaviors, headache, anxiety, insomnia, chest pain, nausea, vomiting, urinary incontinence, dyspnea, pruritus Contraindications Contraindicated in patients hypersensitive to drug. Not approved for use in children with depression. Drug Interactions (include IV compatibility/incompatibility) Antihypertensives, Benzodiazepine, carbamazepine, CNS depressants, Ketoconazole, Metoclopramide, Opioid class warning, Potential CYP2D6 inhibitors, grapefruit juice, alcohol use Antidote (include dosage, route, & frequency) None Nursing Implications (including client teaching)  Black Box W Warning: arning: Drug may increase the risk of suicidal thinking and

Mechanisms of Action

Thought to exert partial agonist activity at dopamine 2 and 5-HT1A receptors and antagonist activity at 5-HT 2A receptors





 

behavior in children, adolescents, and young adults ages 18 to 24 during the first 2 months of treatment, especially in those with major depressive or other psychiatric disorder. Monitor patients for worsening or emergence of suicidal thoughts and behaviors. Black Box W arning: Advise families and caregivers to closely observe patient Warning: for clinical worsening, suicidality, or unusual changes in behavior. Alert: NMS may occur. Monitor patient for hyperpyrexia, muscle rigidity, altered mental status, irregular pulse or BP, tachycardia, diaphoresis, and cardiac arrhythmias. If signs and symptoms of NMS occur, immediately stop drug and notify prescriber. Alert: Monitor patient for symptoms of metabolic syndrome (significant weight gain and increased BMI, HTN, hyperglycemia, hypercholesterolemia, and hypertriglyceridemia)....